title: Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.
abstract: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
authors: Christina A
authors: CA
authors: von Roemeling
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
authors: Derek C
authors: DC
authors: Radisky
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
authors: Laura A
authors: LA
authors: Marlow
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
authors: Simon J
authors: SJ
authors: Cooper
authors: Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
authors: Stefan K
authors: SK
authors: Grebe
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
authors: Panagiotis Z
authors: PZ
authors: Anastasiadis
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
authors: Han W
authors: HW
authors: Tun
authors: Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida. copland.john@mayo.edu.
authors: John A
authors: JA
authors: Copland
mesh_terms: D002097:C-Reactive Protein / Q000235:genetics* / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D002470:Cell Survival / Q000235:genetics; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D009362:Neoplasm Metastasis / Q000235:genetics / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000235:genetics* / Q000378:metabolism; D018091:Receptors, AMPA / Q000235:genetics* / Q000378:metabolism; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000378:metabolism; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D009419:Nerve Tissue Proteins; D018091:Receptors, AMPA; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D000099153:Pentraxins; C104724:glutamate receptor ionotropic, AMPA 4